Wenger David A, Luzi Paola
Department of Neurology Sidney Kimmel College of Medicine at Thomas Jefferson University Philadelphia Pennsylvania USA.
JIMD Rep. 2020 Apr 4;54(1):61-67. doi: 10.1002/jmd2.12117. eCollection 2020 Jul.
Lysosomal disorders are diseases that involve mutations in genes responsible for the coding of lysosomal enzymes, transport proteins, activator proteins and protein processing enzymes. These defects lead to the storage of specific metabolites within lysosomes resulting in a great variety of clinical features depending on the tissues with the storage, the storage products and the extent of the storage. The methods for rapidly diagnosing patients started in the late 1960's when the enzyme defects were identified eliminating the need for tissue biopsies. The first requests for diagnostic help in this laboratory came in 1973. In that year, patients with Krabbe disease and Niemann-Pick type A were diagnosed. Since that time samples from about 62 000 individuals have been received for diagnostic studies, and 4900 diagnoses have been made. The largest number of diagnosed individuals had metachromatic leukodystrophy and Krabbe disease because of our research interest in leukodystrophies. A number of new disorders were identified and the primary defects in other disorders were clarified. With new methods for diagnosis, including newborn screening, molecular analysis, microarrays, there is still a need for biochemical confirmation before treatment is considered. With new treatments, including gene therapy, stem cell transplantation, enzyme replacement used alone or in combination becoming more available, the need for rapid, accurate diagnosis is critical.
溶酶体病是一类涉及负责编码溶酶体酶、转运蛋白、激活蛋白和蛋白质加工酶的基因突变的疾病。这些缺陷导致特定代谢产物在溶酶体内蓄积,根据蓄积的组织、蓄积产物和蓄积程度的不同,会产生各种各样的临床特征。快速诊断患者的方法始于20世纪60年代末,当时发现了酶缺陷,不再需要进行组织活检。该实验室收到的第一份诊断求助请求是在1973年。在那一年,诊断出了患有克拉伯病和A型尼曼-匹克病的患者。从那时起,已收到约62000人的样本用于诊断研究,并做出了4900例诊断。由于我们对白质营养不良的研究兴趣,诊断出人数最多的是异染性脑白质营养不良和克拉伯病。发现了一些新的疾病,并阐明了其他疾病的主要缺陷。随着包括新生儿筛查、分子分析、微阵列在内的新诊断方法的出现,在考虑治疗之前仍需要进行生化确认。随着包括基因治疗、干细胞移植、单独或联合使用酶替代疗法在内的新治疗方法越来越容易获得,快速、准确诊断的需求至关重要。